in the news

Four Key Considerations to Help Prepare for the Next Public Health Threat

As a CDMO, Emergent has been working for more than two decades to develop, manufacture and deliver protections against public health threats and deliver vaccines and therapeutic products for clients. In it's work with biopharma and biotechnology businesses, as well as government and nongovernment organizations, Emergent provides the technology, expertise and talent to help quickly and efficiently ramp up manufacturing and development for its clients' products.

During COVID-19, Emergent deployed new processes, and technologies to manufacture novel coronavirus vaccine and therapeutic candidates for CDMO clients. That experience has doubled as a learning opportunity for the future. In this article, Emergent team members reflect on lessons learned through COVID-19 and share four consideration to help prepare for the next public health threat.

Read Article

 

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

  • Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies,...
READ MORE

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™

GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021  Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. ...

READ MORE

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

  • Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...
READ MORE